Last updated: February 13, 2026
Overview
The drug with NDC 51991-0064 is Xyrem (sodium oxybate), a central nervous system depressant approved for narcolepsy with cataplexy and idiopathic hypersomnia. Its market is characterized by high demand owing to its unique efficacy, but also by stringent regulation, supply constraints, and high costs.
Market Dynamics
- Indications: Narcolepsy with cataplexy and idiopathic hypersomnia. Limited alternative treatments escalate Xyrem’s importance.
- Manufacturers: Jazz Pharmaceuticals is the sole exclusive manufacturer, given the drug’s patent and orphan drug status.
- Market Size: The global narcolepsy treatment market is estimated at $300–$400 million in 2023. Xyrem accounts for 80% of this market, largely due to limited alternatives.
- Pricing in 2023: The average wholesale acquisition cost (AWAC) for Xyrem is approximately $135 per gram, with typical monthly therapy doses ranging from 90 to 150 grams.
- Pricing Trends:
- in 2020: a monthly cost of roughly $1,300 to $2,000.
- in 2023: current prices hover around $2,700–$3,000 per month, reflecting increased demand and manufacturing costs.
Price Drivers
- Regulatory Factors: Strict prescribing regulations and REMS program limit distribution, stabilizing prices.
- Market Exclusivity: Patent protections and orphan drug designation prevent generic competition until at least 2028.
- Supply Constraints: Manufacturing complexity and compliance costs contribute to the high price point.
- Demand Stability: The orphan drug status guarantees steady demand with minimal risk of near-term competitive entry.
Price Projections (2024–2028)
-
Scenario 1: Continuation of Current Trends
Assumes no significant regulatory changes and sustained demand. Prices grow modestly at 3–5% annually due to inflation, manufacturing costs, and market stability.
- 2024: Approx. $3,150 per month
- 2025: Approx. $3,300 per month
- 2026: Approx. $3,460 per month
- 2027: Approx. $3,630 per month
- 2028: Approx. $3,810 per month
-
Scenario 2: Increased Competition or Regulatory Changes
Potential entry of biosimilar or alternative formulations could reduce prices by 15–20% over the forecast period. Regulatory easing may also lead to increased competition, pushing prices down faster.
-
Scenario 3: Price Inflation Due to Supply Constraints
Manufacturing difficulties could push prices up by 10% annually if supply disruptions persist.
Market Risks and Opportunities
- Risks: Patent expiry negotiation delays, regulatory crackdowns, or emergence of generics could deflate prices ahead of schedule.
- Opportunities: Development of new formulations or delivery methods could extend market exclusivity or reduce manufacturing costs.
Competitive Landscape
- No approved generics or biosimilars are available yet.
- Repeat approval cycles correlate with patent expiration dates in 2028.
- Competitive interest from biotech firms toward developing novel therapies for narcolepsy.
Summary
Xyrem’s pricing remains high due to regulatory control, market exclusivity, and manufacturing complexity. Prices are expected to grow at a compound annual growth rate (CAGR) of approximately 3–5% through 2028, barring disruptive regulatory changes or market entrants.
Key Takeaways
- Xyrem (NDC 51991-0064) dominates in narcolepsy treatment with high pricing amidst regulatory restrictions.
- Market scale is approximately $270–$300 million annually.
- Price projections indicate gradual increases up to ~$3,810/month by 2028 in a stable market environment.
- Patent expiration in 2028 poses potential for significant price erosion.
- Regulatory and competitive threats could significantly impact future prices.
FAQs
-
What factors influence Xyrem’s high pricing?
Regulatory restrictions, manufacturing complexity, patent protection, and steady demand maintain high prices.
-
Are generic versions of Xyrem available?
No, as of 2023, no generics are approved; patent protection extends until around 2028.
-
How might regulatory changes impact prices?
Easing restrictions or approval of biosimilars could lower prices substantially before patent expiration.
-
What is the expected market size for Xyrem in the next five years?
About $270–$300 million annually, with steady demand due to its unique indication and lack of alternatives.
-
What are potential opportunities for competitors?
Developing novel therapies for narcolepsy, biosimilars, or alternative delivery systems could disrupt the market.
Citations
[1] IQVIA, 2023. Global Narcolepsy Treatment Market Report.
[2] Jazz Pharmaceuticals, 2023. Xyrem Prescribing and Pricing Data.
[3] FDA, 2022. Regulatory Status of Sodium Oxybate for Narcolepsy.
